Daniel specialises in biologics and pharmaceuticals, with particular expertise in protein therapeutics, medicinal chemistry and vaccine technology. Much of his time is spent handling EPO opposition and UPC revocation proceedings, in which he has extensive experience both at first instance and appeal. He is a sought-after oral advocate and led the EPO oppositions linked to the widely cited US cases AbbVie v. Janssen and Amgen v. Sanofi.
Aside from his opposition and UPC practice, Daniel carries out a range of patent work, including original drafting, prosecution at the EPO and overseas, opinions, and freedom to operate analyses. He is regularly involved in pan European litigation and has particular experience leading EPO and UPC strands of complex international disputes. He is passionate about helping his clients bring their innovative medicines to market, with robust protection and free of competitor patents. Daniel has an in-depth knowledge of supplementary protection certificates (SPCs) for authorised medicines, having coordinated several high profile SPC portfolios across the EU and advised on the infringement and validity of third party SPCs. He has contributed to several SPC cases at the Court of Justice of the European Union over the years, including Queensland (C-630/10), Neurim (C-130/11) and Abraxis (C-443/17).
Daniel has a global client base, from the US and Europe to Japan and Australia. He is regularly in our Munich office and Europe more generally, where he focuses on the innovative pharmaceutical sectors of Germany, Switzerland and Denmark in particular.
